| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised … MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ... The Lancet 395 (10231), 1208-1216, 2020 | 1400 | 2020 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 641 | 2021 |
| The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study PJ Roach, R Francis, L Emmett, E Hsiao, A Kneebone, G Hruby, T Eade, ... Journal of Nuclear Medicine 59 (1), 82-88, 2018 | 378 | 2018 |
| Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG … RJ Francis, MJ Byrne, AA van der Schaaf, JA Boucek, AK Nowak, ... Journal of Nuclear Medicine 48 (9), 1449-1458, 2007 | 233 | 2007 |
| A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours RJ Francis, SK Sharma, C Springer, AJ Green, LD Hope-Stone, L Sena, ... British journal of cancer 87 (6), 600-607, 2002 | 203 | 2002 |
| Post-radioembolization yttrium-90 PET/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres YH Kao, JD Steinberg, YS Tay, GKY Lim, J Yan, DW Townsend, ... EJNMMI research 3, 1-12, 2013 | 192 | 2013 |
| A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters AK Nowak, RJ Francis, MJ Phillips, MJ Millward, AA van der Schaaf, ... Clinical Cancer Research 16 (8), 2409-2417, 2010 | 130 | 2010 |
| TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer … MS Hofman, L Emmett, J Violet, A Y. Zhang, NJ Lawrence, M Stockler, ... BJU international 124, 5-13, 2019 | 129 | 2019 |
| A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to … MS Hofman, DG Murphy, SG Williams, T Nzenza, A Herschtal, ... BJU international 122 (5), 783-793, 2018 | 127 | 2018 |
| Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden J Creaney, RJ Francis, IM Dick, AW Musk, BWS Robinson, MJ Byrne, ... Clinical Cancer Research 17 (5), 1181-1189, 2011 | 108 | 2011 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 107 | 2022 |
| 3-Year freedom from progression after 68Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial L Emmett, R Tang, R Nandurkar, G Hruby, P Roach, JA Watts, T Cusick, ... Journal of Nuclear Medicine 61 (6), 866-872, 2020 | 107 | 2020 |
| A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma AK Nowak, MJ Millward, J Creaney, RJ Francis, IM Dick, A Hasani, ... Journal of thoracic oncology 7 (9), 1449-1456, 2012 | 102 | 2012 |
| A Phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti–carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 … A Mayer, RJ Francis, SK Sharma, B Tolner, CJ Springer, J Martin, ... Clinical Cancer Research 12 (21), 6509-6516, 2006 | 98 | 2006 |
| A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma AK Nowak, AM Cook, AM McDonnell, MJ Millward, J Creaney, RJ Francis, ... Annals of Oncology 26 (12), 2483-2490, 2015 | 95 | 2015 |
| Interventional therapies for malignant pleural effusions: the present and the future R Thomas, R Francis, HE Davies, YCG Lee Respirology 19 (6), 809-822, 2014 | 93 | 2014 |
| TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC … MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020 | 79 | 2020 |
| Is prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial RE de Feria Cardet, MS Hofman, T Segard, J Yim, S Williams, RJ Francis, ... European urology 79 (3), 413-418, 2021 | 68 | 2021 |
| A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared … M McCarthy, R Francis, C Tang, J Watts, A Campbell International Journal of Radiation Oncology* Biology* Physics 104 (4), 801-808, 2019 | 66 | 2019 |
| TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Lancet 397 (10276), 797-804, 2021 | 61 | 2021 |
